Caio Max Rocha Lima to Disease Progression
This is a "connection" page, showing publications Caio Max Rocha Lima has written about Disease Progression.
Connection Strength
0.242
-
Bayraktar S, Bayraktar UD, Rocha-Lima CM. Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer. World J Gastroenterol. 2010 Feb 14; 16(6):673-82.
Score: 0.074
-
Raez LE, Santos ES, Lopes G, Rosado MF, Negret LM, Rocha-Lima C, Tolba K, Farfan N, Hamilton-Nelson K, Silva O, Roman E. Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung cancer (NSCLC). Lung Cancer. 2006 Sep; 53(3):347-53.
Score: 0.058
-
Rocha Lima CM, Green MR, Rotche R, Miller WH, Jeffrey GM, Cisar LA, Morganti A, Orlando N, Gruia G, Miller LL. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol. 2004 Sep 15; 22(18):3776-83.
Score: 0.051
-
Rocha Lima CM, Savarese D, Bruckner H, Dudek A, Eckardt J, Hainsworth J, Yunus F, Lester E, Miller W, Saville W, Elfring GL, Locker PK, Compton LD, Miller LL, Green MR. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol. 2002 Mar 01; 20(5):1182-91.
Score: 0.043
-
Marsh Rde W, Rocha Lima CM, Levy DE, Mitchell EP, Rowland KM, Benson AB. A phase II trial of perifosine in locally advanced, unresectable, or metastatic pancreatic adenocarcinoma. Am J Clin Oncol. 2007 Feb; 30(1):26-31.
Score: 0.015